AASCIT - Journal - All Issues

ISSN: 2375-3838

International Journal of Clinical Medicine Research

The Journal

Manuscript Information

Clinical Chemistry and Microbiology Studies in Egyptian Thalassemic Children Infected with Hepatitis C Virus

International Journal of Clinical Medicine Research
Vol.4 , No. 5, Publication Date: Nov. 16, 2017, Page: 65-71

420 Views Since November 16, 2017, 243 Downloads Since Nov. 16, 2017

Paper in PDF (360K)

Follow on

Authors

[1]	Mahmoud Gomaa, Section of Microbiology, Faculty of Science, Tanta University, Tanta, Egypt.
[2]	Mostafa Mohamed El-Sheekh, Section of Microbiology, Faculty of Science, Tanta University, Tanta, Egypt.
[3]	Ahmed Samy El-Shafey, Section of Microbiology, Faculty of Science, Tanta University, Tanta, Egypt.
[4]	Metwally Abdel-Azeem Metwally, Section of Microbiology, Faculty of Science, Tanta University, Tanta, Egypt.
[5]	Mohamed Ramadan El-Shanshory, Department of Pediatrics, Faculty of Medicine, Tanta University, Tanta, Egypt.
[6]	Manal Abdel-Wahed Eid, Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt.

Abstract

The present study was conducted to evaluate the efficiency of natural Spirulina preparation in the treatment thalassemic children infected with hepatitis C virus (HCV). Twenty five (25) Egyptian thalassemic children infected with HCV (12 male, and 13 female children), aged from 3 to 8 years were subjected in this study. Volunteers were supplied with dried Spirulina (250 mg /kg /day) by oral uptake with their usual thalassemic drugs. Throughout 6 months treatment, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), albumin, total bilirubin, and quantitative (real time) PCR for HCV were assessed. The main parameters of healing for these complicated cases were the promising appearance of 3 cases with –ve (0.0 IU/ml) HCV count in patient serum by real time PCR quantification; and lowering of ALT, and AST less than 40 U/L in 13 female cases, and 12 male cases, respectively after 6 months of treatment with Spirulina.

Keywords

Hepatitis C Virus (HCV), Thalassemia, Spirulina

Reference

[01]	John, K. (2011): Complications of Thalassemia. Mayo Clinic.
[02]	Triantos, C.; Kourakli, A.; Kalafateli, M.; Giannakopoulou, D.; and Koukias, N. (2013): Hepatitis C in patients with β-thalassemia major. A single-centre experience. Hematol., 92: 739-46.
[03]	Nakano, T.; Lau, GM.; and Lau, G. (2011): An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int., 32: 339-345.
[04]	Hanafiah, M.; Groeger, J.; Flaxman, A.; and Wiersma, S. (2013): Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology, 57 (4): 1333–1342.
[05]	Manns, M.; Foster, G.; Rockstroh, J.; Zeuzem, S.; Zoulim, F.; and Houghton, M. (2007): The way forward in HCV treatment-finding the right path. Nat. Rev. Drug Discov., 6: 991-1000.
[06]	Alavian, S.; Tabatabaei, S.; and Tess, K. (2010): Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. J. Viral Hepat., 17: 236-244.
[07]	Elias E. Mazokopakis, Maria G. Papadomanolaki Andreas A. Fousteris, Dimitrios A. Kotsiris, Ioannis M. Lampadakis, and Emmanuel S. Ganotakis. (2014). The hepatoprotective and hypolipidemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population with non-alcoholic fatty liver disease: a prospective pilot study. Ann Gastroenterol.; 27 (4): 387–394.
[08]	Tokusoglu, O.; and Uunal, M. (2003): Biomass Nutrient Profiles of Three Microalgae: Spirulina platensis, Chlorella vulgaris, and Isochrisis galbana. J. Food Sci., 68: 1144-1148.
[09]	Chamorro, G.; Salazar, M.; Favila, L.; and Bourges, H. (1996): Pharmacology and toxicology of Spirulina alga. Rev. Invest. Clin., 48: 389-399.
[10]	Hayashi, K.; Hayashi, T.; and ojima, I. (1993): A natural sulfated polysaccharide, calcium Spirulina, isolated from Spirulina platensis: invitro and in vivo evaluation of anti-Herpes simplex virus and anti-human immunodeficiency virus activities. AIDS Research and Human Retroviruses, 12: 1463-1471.
[11]	Ayehunie, S.; Belay, A.; Baba, T.; and Ruprecht, R. (1998): Inhibition of HIV-1 replication by an aqueous extract of Spirulina platensis. J. AIDS and Human Retrovirology, 18: 7-12.
[12]	Health Systems Profile- Egypt, (2006): Regional Health Systems Observatory- EMRO, World Health organization
[13]	Costa J. A. C., Morais M. G. Microalgae for food production. In: Soccol C. R., Pandey A., Larroche C., editors.(2013): Fermentation Process Engineering in the Food Industry. Taylor & Francis; 2013. p. p. 486.
[14]	Schumann, G.; and Klauke, R. (2003): New IFCC reference procedures for the determination of catalytic activity concentrations of five enzymes in serum: Preliminary upper reference limits obtained in hospitalized subjects. Clin. Chim. Acta., 327: 69-79.
[15]	Schumann, G.; Bonora, R.; and Ceriotti, F. (2002): IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37°C. International Federation of Clinical Chemistry and Laboratory Medicine; Part-5; Reference procedure for the measurement of catalytic concentration of aspartate aminotransferase. Clin. Chem. Lab. Med., 40: 725-733.
[16]	Rodkey, F. (1964): Tris (hydroxymethyl) Aminomethane as a Standard for Kjeldahl Nitrogen Analysis. Clin. Chem., 10: 606-610.
[17]	Doumas, B.; Watson, W.; and Biggs, H. (1971): Albumin standards and measurement of serum albumin with bromocresol green. Clin. Chim. Acta., 31: 87- 96.
[18]	Malloy, H.; and Evelyn, K. (1937): The determination of bilirubin with the photoelectric colorimeter. J. Biol. Chem., 119: 481- 490.
[19]	Burtis, C.; Ashwood, E.; and Bruns, D. (2005): Text book of clinical chemistry and molecular diagnostics, 4^th ed., WB Saunders Co. Press, USA.
[20]	Young, D. (1995): Effects of drugs on clinical lab tests, 4^th ed., AACC Press, London.
[21]	Rasmussen, R. (2001): Quantification on the Light Cycler. In: Meuer, S.; Wittwer, C.; and Nakagawara, K. ed., Rapid Cycle Real-time PCR, Methods and Applications. Springer Press, Heidelberg, 5: 21–34.
[22]	Lee, A.; and Werth, V. (2004): Activation of autoimmunity following use of immunostimulatory herbal supplements. Arch. Dermatol., 140: 723-735.
[23]	Puoti, M.; Guido, A.; Mangia, M.; Persico, D.; Prati, C. (2003): Clinical management of HCV carriers with normal aminotransferase levels In: J. Digestive and Liver Disease, 35: 362-369.
[24]	Kwong, I.; Najera, J.; Bechtel, S.; Bowden, J.; and Fitzgibbon, P. (2011): equence and Phenotypic Analysis for Resistance Monitoring in Hepatitis C Virus Drug Development: Recommendations from the HCVDRAG. In: J. of Gastroenterology, 140: 755-760.
[25]	Mavromara, A.; Sall, O.; Kalinina, V.; Horm, A.; and Budkowska, P. (2005): The impact of HCV diversity on diagnosis tools for HCV infection. In: J. of Médecine et Maladies Infectieuses, 35: 103-104.
[26]	Albertoni, C.; Arnoni, P.; Araújo, F.; Carvalho, J.; and Barreto, A. (2010): Signal to cut-off (S/CO) ratio and detection of HCV genotype 1 by real-time PCR one-step method: is there any direct relationship? In: The Brazilian Journal of Infectious Diseases, 14: 147-152.
[27]	Haid, A.; Novodomská, J.; Gentzsch, C.; and Grethe, S. (2012): A Plant-Derived Flavonoid Inhibits Entry of All HCV Genotypes into Human Hepatocytes. In: J. Gastroenterology, 143: 213-222.
[28]	Tong, S.; Bogen, R.; and Chase, V. (2008): Characterization of resistance mutations against HCV ketoamide protease inhibitors. In: J. Antiviral Res., 77: 177-185.